This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Asciminib oral


Oral formulations of asciminib.

Drugs List

  • asciminib 20mg tablets
  • asciminib 40mg tablets
  • SCEMBLIX 20mg tablets
  • SCEMBLIX 40mg tablets
  • Therapeutic Indications


    Philadelphia chromosome positive (Ph+) chronic myeloid leukaemia (CML)

    Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in chronic phase in adult patients, previously treated with two or more tyrosine kinase inhibitors, and without a known T315l mutation.


    Whilst the doses stated below are those recommended by the manufacturer, local cancer network protocols for the relevant indication should be consulted.


    80mg once daily at the same time each day or 40mg twice daily at 12-hour intervals.

    Additional Dosage Information

    Dose modifications
    Starting dose: 80mg once daily
    Reduced dose: 40mg once daily
    Resumed dose: 80mg once daily

    Starting dose: 40mg twice daily
    Reduced dose: 20mg twice daily
    Resumed dose: 40mg twice daily

    Asciminib should be permanently discontinued in patients unable to tolerate a total daily dose of 40mg.

    Dose modifications for adverse reactions
    Thrombocytopenia (absolute neutrophil count (ANC) less than 1.0 x 10 to power 10/L and/or platelet count (PLT) less than 50 x 10 to power 9/L): Withhold asciminib treatment until resolved to ANC greater than or equal to 1 x 10 to the power 10/L and/or PLT greater than or equal to 50 x 10 to the power 10/L. If resolved within 2 weeks then resume asciminib treatment at starting dose. If resolves after more than 2 weeks then resume asciminib at a reduced dose. For recurrent severe thrombocytopenia and/or neutropenia, withhold asciminib treatment until resolved to ANC greater than or equal to 1 x 10 to the power 9/L and PLT greater than or equal to 50 x 10 to the power 9/L, then resume asciminib at a reduced dose.

    Asymptomatic amylase and/or lipase elevation greater than 2 x ULN: Withhold asciminib treatment until resolved to less than 1.5 x ULN. If resolved then resume at a reduced dose. If events reoccur at a reduced dose then permanently discontinue asciminib treatment. If not resolved then permanently discontinue asciminib treatment. Perform diagnostic tests to exclude pancreatitis.

    Grade 3 or higher non-haematological adverse reactions: Withhold asciminib until resolved to grade 1 or lower. If resolved then resume asciminib at a reduced dose. If not resolved then permanently discontinue treatment with asciminib.


    Children under 18 years
    Long QT syndrome
    Torsade de pointes

    Precautions and Warnings

    Family history of long QT syndrome
    Females of childbearing potential
    History of treatment with anthracyclines
    Electrolyte imbalance
    Glucose-galactose malabsorption syndrome
    History of cardiac disorder
    History of hepatitis B
    History of pancreatitis
    History of torsade de pointes
    History of uncontrolled cardiovascular disorder
    Lactose intolerance
    Moderate hepatic impairment

    Correct electrolyte disorders before treatment
    Advise ability to drive/operate machinery may be affected by side effects
    Before initiating screen all patients for hepatitis B infection
    Treatment to be initiated by specialist
    Contains lactose
    Advise patient to have no food for 2 hours before and 1 hour after dose
    Avoid oral products containing hydroxypropyl-beta-cyclodextrin
    Consult local policy on the safe use of oral anti-cancer drugs
    Staff: Not to be handled by pregnant staff
    Exclude pregnancy prior to initiation of treatment
    Perform ECG before and during treatment
    Monitor blood counts every 2 weeks for first 3 months then monthly
    Monitor blood pressure regularly
    Monitor for active hepatitis B during therapy and for several months after
    Monitor pancreatic function
    Monitor serum amylase and lipase monthly
    Monitor serum electrolytes
    Predisposition QT prolongation: Counsel patient on symptoms of arrhythmias
    Reactivation of hepatitis B may occur in chronic carriers
    Interrupt therapy if neutrophil count <1.0x10 to the power 9/L
    Interrupt treatment if platelet count <50 x 10 to the power of 9/L
    Suspend treatment and/or reduce dose in grade 3 non-haematological toxicity
    Suspend treatment if elevated serum lipase/amylase with abdominal symptoms
    Advise patient not to take St John's wort concurrently
    Female: Contraception required during and for 3 days after treatment
    Breastfeeding: Do not breastfeed during and for 3 days after treatment

    Caution should be exercised during concomitant administration of asciminib with hydroxypropyl-beta-cyclodextrin containing oral products, as bioavailability of asciminib may be reduced.

    Pregnancy and Lactation


    Asciminib is contraindicated during pregnancy.
    The manufacturer recommends that asciminib is not used during pregnancy or in women of childbearing potential not using contraception. There is no data available from the use of asciminib in pregnant women, however animal studies have shown reproductive toxicity.


    Asciminib is contraindicated during breastfeeding.
    The manufacturer does not recommend breastfeeding during treatment with asciminib and for at least 3 days after stopping asciminib treatment. There are no data on the effects of asciminib on breastfed infants, and it is unknown whether asciminib is excreted in human milk.

    Side Effects

    Abdominal pain
    Alterations in pancreatic enzymes
    Blurred vision
    Creatine phosphokinase increased
    Decreased appetite
    Dry eyes
    Febrile neutropenia
    Increases in hepatic enzymes
    Lower respiratory tract infection
    Musculoskeletal pain
    Non-cardiac chest pain
    Pleural effusion
    Prolongation of QT interval
    Serum bilirubin increased
    Upper respiratory tract infection


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: September 2022

    Reference Sources

    Summary of Product Characteristics: Scemblix 20mg film-coated tablets. Novartis Pharmaceuticals UK Ltd. Revised June 2022.
    Summary of Product Characteristics: Scemblix 40mg film-coated tablets. Novartis Pharmaceuticals UK Ltd. Revised June 2022.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.